Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytolysis (ADCC) Relative to Other Anti-CD20 mAbs

site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
Drug Category: Array
Conference Category: Array
Lead Author: Foley J, et al.
Published Date: 25/04/2023
Download Link: /wp-content/uploads/2023/04/Foley-AAN_2023.pdf
Download Text: Download
Popup Confirmation?:
astra-migrate-meta-layouts: set
Scroll to Top